Global Procalcitonin Testing (In Vitro Diagnostics) Market Analysis and Forecast, 2015-2021 and 2021-2030

DUBLIN, May 10, 2022–(BUSINESS WIRE)–The “Procalcitonin Testing (In Vitro Diagnostics) – Global Market Analysis and Forecast Model” report has been added to from ResearchAndMarkets.com offer.

Procalcitonin Testing (In Vitro Diagnostics) – Global Market Analysis and Forecasting Model (COVID-19 Market Impact) is designed to visualize quantitative market trends in the therapeutic area of ​​In Vitro Diagnostics.

Sepsis is a life-threatening condition characterized by organ dysfunction caused by a patient’s dysregulated response to infection. Sepsis is related to but distinct from sepsis, which is the spread of bacterial infection through the bloodstream; sepsis is the dysregulated host response to this infection.

Advanced sepsis is associated with a high mortality rate (20-30%) with contributing factors such as late diagnosis, inappropriate clinical management and suboptimal quality of care. The age distribution of people with sepsis is largely biphasic, primarily affecting newborns (and their mothers) and the elderly; older patients with sepsis tend to have a wide range of comorbidities. Sepsis can quickly progress to a condition known as septic shock, where profound circulatory, cellular, and metabolic abnormalities present a higher risk of mortality.

The dosage of procalcitonin makes it possible to distinguish a bacterial infection from a viral infection and to monitor the effectiveness of an antibiotic treatment. However, these tests are not used exclusively for patients with sepsis. Procalcitonin can be used in patients with lower respiratory tract infections (LRTIs), bacterial pneumonia, or to monitor patients requiring mechanical ventilation for potential infection.

Respiratory infections, including various pneumonias, are the most common cause of sepsis, and ventilated patients may also be sepsis in addition to other comorbidities.

Due to the non-mutually exclusive nature of these conditions, sepsis was chosen as the primary disease state and indication for this market model. All other indications requiring procalcitonin testing are intended to be covered under “Other Indications” on each country tab in this template.

Scope

  • CMO leaders who need to have an in-depth understanding of the Procalcitonin Testing market to make strategic planning and investment decisions.

  • Procurement and procurement managers who need to understand the critical elements of the supply base in order to make decisions regarding vendor selection and management.

  • Private equity investors who need a deeper understanding of the market to identify and assess potential investment targets.

Reasons to buy

  • To understand the impact of COVID-19 on the Procalcitonin Testing Market.

  • Develop and design your licensing and out-licensing strategies through a review of pipeline products and technologies, and identifying the companies with the strongest pipeline.

  • Develop business strategies by understanding the trends shaping and driving the Procalcitonin Testing market.

  • Generate revenue by understanding the key trends, innovative products and technologies, market segments, and companies that are likely to impact the Procalcitonin Testing Market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the company’s share among market leaders.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Track device sales in the global and country-specific procalcitonin testing market from 2015 to 2030.

  • Organize your sales and marketing efforts by identifying the categories and market segments that present the maximum opportunities for consolidations, investments and strategic partnerships.

Companies covered

  • Abbott Laboratories

  • Danaher Corp.

  • Backman Coulter

  • F. Hoffmann-La Roche SA

  • DiaSorin SpA, bioMérieux SA

  • Siemens Healthineers AG

  • Ortho-clinical diagnosis and

  • Diazyme Laboratories Inc.

For more information about this report visit https://www.researchandmarkets.com/r/1yze55

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220510006291/en/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Officer
[email protected]

For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900

Comments are closed.